Inactive

The Department of Health and Human Services, National Institutes of Health, NationalCancer Institute (NCI), Center for Cancer Research (CCR), Metastasis Biology Section ofthe Surgical Oncology Program... The Department of Health and Human Services, National Institutes of Health, NationalCancer Institute (NCI), Center for Cancer Research (CCR), Metastasis Biology Section ofthe Surgical Oncology Program (SOP) plans to procure, on a sole source basis, bioinformatic analysis services for data generated by SOP’s ex vivo human tumor systems from: BostonGene Corporation 95 Sawyer Rd Waltham, MA 02453 The response close date of the notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be awarded pursuant to the authority in FAR Part 13 and is exempt from the requirements of FAR Part 6. BostonGene provides state-of-the-art AI-driven next-generation analytics technologies to the general public that allows the unification and classification of large bioinformatic datasets, using their proprietary pipelines (PMID: 33771855 ). These pipelines include artificial intelligence-based analytic algorithms to examine tumor ecosystems and their integration with corresponding transcriptomics, based on multiplex single-cell special imaging and gene expression profiling. Further, BostonGene has developed its own unique planetary map of patient tumors based on DNA mutations and transcriptomic profiling (PMID: 34019806 ). This analysis can only be applied by BostonGene. This map enables the transcriptomic analysis of heterogeneous tumor microenvironments and their classification into distinct conserved microenvironment subtypes. Currently, BostonGene is the only company that provides such comprehensive and integrated analysis. BostonGene has no previous contractual relationship with the Government but successfully performed equivalent work under NIH’s Intramural Research Program (grant 1P01CA229100 from the National Cancer Institute). This work resulted in the accelerated development of improved therapies for several aggressive lymphoma cancer types. NCI’s Surgical Oncology Program is seeking to utilize this same technology to aid in the development of novel combinational therapies for solid tumors with the use of the Hernandez lab Human Tumor Systems. This notice is not a request for competitive quotations. However, if any interested party,especially a small business, believes it can meet the above requirements, it may submit aproposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain sufficient details to allow NCI to determine if the party can perform the requirement. Responses must be sent via email to the Contract Specialist, John Russell, at john.russell3@nih.gov by no later than 12:00 PM EST, on Thursday, August 18, 2022 (8/18/22). A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must be registered and have valid certification through SAM.GOV. Reference: (75N91022Q00171) on all correspondence. ***Please reference the attached Draft Statement of Work for more details pertaining to the nature of the work to be performed, as well as Terms and Conditions. ***